Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 145

1.

Irbesartan reduces the albumin excretion rate in microalbuminuric type 2 diabetic patients independently of hypertension: a randomized double-blind placebo-controlled crossover study.

Sasso FC, Carbonara O, Persico M, Iafusco D, Salvatore T, D'Ambrosio R, Torella R, Cozzolino D.

Diabetes Care. 2002 Nov;25(11):1909-13.

PMID:
12401731
2.

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group.

N Engl J Med. 2001 Sep 20;345(12):870-8.

3.
4.

Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.

Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Drury PL, Esmatjes E, Hricik D, Parikh CR, Raz I, Vanhille P, Wiegmann TB, Wolfe BM, Locatelli F, Goldhaber SZ, Lewis EJ; Irbesartan Diabetic Nephropathy Trial. Collaborative Study Group.

Ann Intern Med. 2003 Apr 1;138(7):542-9.

PMID:
12667024
5.

Treatment of diabetic nephropathy with angiotensin II receptor antagonist.

Lewis EJ, Lewis JB.

Clin Exp Nephrol. 2003 Mar;7(1):1-8. Review.

PMID:
14586737
6.

[Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].

Parving HH, Lehnert H, Brøchner-Mortensen J, Gomis R, Andersen S, Arner P.

Ugeskr Laeger. 2001 Oct 1;163(40):5519-24. Danish.

PMID:
11601118
8.

Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy.

Croom KF, Curran MP, Goa KL, Perry CM.

Drugs. 2004;64(9):999-1028. Review.

PMID:
15101793
9.

Effect of irbesartan on nitrotyrosine generation in non-hypertensive diabetic patients.

Ceriello A, Assaloni R, Da Ros R, Maier A, Quagliaro L, Piconi L, Esposito K, Giugliano D.

Diabetologia. 2004 Sep;47(9):1535-40. Epub 2004 Aug 14.

PMID:
15316606
11.

Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria.

Andersen S, Bröchner-Mortensen J, Parving HH; Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria Study Group.

Diabetes Care. 2003 Dec;26(12):3296-302.

PMID:
14633817
12.

A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension.

Palmer AJ, Valentine WJ, Tucker DM, Ray JA, Roze S, Annemans L, Lapuerta P, Chen R, Gabriel S, Carita P, Rodby RA, de Zeeuw D, Parving HH, Laville M.

Curr Med Res Opin. 2006 Nov;22(11):2095-100.

PMID:
17076969
13.

The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group.

Rodby RA, Rohde RD, Clarke WR, Hunsicker LG, Anzalone DA, Atkins RC, Ritz E, Lewis EJ.

Nephrol Dial Transplant. 2000 Apr;15(4):487-97.

PMID:
10727543
14.

A clinical trial in type 2 diabetic nephropathy.

Lewis EJ, Hunsicker LG, Rodby RA; Collaborative Study Group.

Am J Kidney Dis. 2001 Oct;38(4 Suppl 1):S191-4.

PMID:
11576953
15.

Long-term effects of Irbesartan treatment and smoking on nucleic acid oxidation in patients with type 2 diabetes and microalbuminuria: an Irbesartan in patients with type 2 diabetes and Microalbuminuria (IRMA 2) substudy.

Broedbaek K, Henriksen T, Weimann A, Petersen M, Andersen JT, Afzal S, Jimenez-Solem E, Persson F, Parving HH, Rossing P, Poulsen HE.

Diabetes Care. 2011 May;34(5):1192-8. doi: 10.2337/dc10-2214. Epub 2011 Mar 31.

16.

[Clinical and health economic implications of early treatment with irbesartan of patients with type 2 diabetes mellitus, hypertension and nephropathy].

Palmer AJ, Roze S, Rodby RA, Valentine WJ, Ritz E, Lehnert H.

Dtsch Med Wochenschr. 2006 Aug 4;131(31-32):1721-6. German.

PMID:
16868875
17.

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group.

N Engl J Med. 2001 Sep 20;345(12):851-60.

18.

Transcapillary escape rate of albumin in type II diabetic patients. The relationship with microalbuminuria and hypertension.

Nannipieri M, Penno G, Rizzo L, Pucci L, Bandinelli S, Mattei P, Taddei S, Salvetti A, Navalesi R.

Diabetes Care. 1997 Jun;20(6):1019-26.

PMID:
9167118
19.
20.

Systematic review on urine albumin testing for early detection of diabetic complications.

Newman DJ, Mattock MB, Dawnay AB, Kerry S, McGuire A, Yaqoob M, Hitman GA, Hawke C.

Health Technol Assess. 2005 Aug;9(30):iii-vi, xiii-163. Review.

Supplemental Content

Support Center